• Wondering whether CONMED at around US$34.77 is starting to look cheap, or if the stock's slide still has further to run? This article walks through what the current price might be implying about the company's value.
• The share price has fallen about 1.1% over the past week, 2.2% over the past month, and 14.2% year to date, with a decline of 34.8% over the past year and around 73% over both three and five years. This may have reset expectations and risk perceptions for many investors.
• Recent coverage around CONMED has focused on how investors are reassessing medical equipment stocks and their valuations in light of changing sentiment toward the sector. That context matters when looking at a stock that has already given up a large amount of value over several years.
• CONMED currently scores a 5 out of 6 valuation score, suggesting it screens as undervalued on most of the checks used in this framework. The sections that follow will walk through those valuation approaches before finishing with an even more useful way to think about what the market price is really telling you.

Approach 1: CONMED Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes CONMED's expected future cash flows and discounts them back to today to estimate what the entire business might be worth in dollars right now.

CONMED's latest twelve month Free Cash Flow is about $125.08 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates project annual Free Cash Flow out to 2035, reaching about $140.84 million in year ten, with interim years ranging from around $194.70 million in 2026 to $133.21 million in 2032. These future cash flows are discounted to reflect risk and the time value of money, then summed to arrive at a total equity value.

On this basis, the DCF model suggests an intrinsic value of about $68.90 per share, compared with a current share price of roughly $34.77. That gap indicates the stock is trading at around a 49.5% discount to this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CONMED is undervalued by 49.5%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: CONMED Price vs Earnings

For a profitable company, the P/E ratio is a useful way to connect what you pay for each share with the earnings that each share currently generates. It gives you a quick sense of how many dollars investors are willing to pay today for one dollar of current earnings.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risks. Higher expected growth or steadier earnings often justify a higher P/E, while higher risk or weaker profitability usually point to a lower one.

CONMED currently trades on a P/E of 19.09x. That sits below the Medical Equipment industry average of about 24.81x and the peer group average of 38.71x. Simply Wall St’s proprietary “Fair Ratio” for CONMED is 28.61x, which is an estimate of what its P/E might be if the market fully reflected factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics.

The Fair Ratio is more tailored than a simple comparison with peers or the broad industry because it adjusts for those company specific factors rather than assuming all Medical Equipment stocks deserve the same multiple. Compared with the current 19.09x P/E, the Fair Ratio of 28.61x suggests the stock is trading below this customised assessment.

Result: UNDERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your CONMED Narrative

Earlier the article mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple way to attach your story about CONMED to the numbers by linking your view of its future revenue, earnings and margins to a Fair Value. You can then compare that Fair Value with the current price to help you decide whether to buy, hold or sell, all within an easy to use tool on Simply Wall St’s Community page that updates automatically when fresh news or earnings arrive. For CONMED, one investor might align with a more cautious Narrative that points to a Fair Value around US$39.0, while another might lean toward a more optimistic Narrative around US$40.0, or even the broader analyst consensus that centers on US$48.40 to US$61.0. These different stories, all based on explicit assumptions, are what drive each investor’s view of what the stock is worth today.

Do you think there's more to the story for CONMED? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.